Literature DB >> 11150301

Specific docking of apolipoprotein A-I at the cell surface requires a functional ABCA1 transporter.

O Chambenoit1, Y Hamon, D Marguet, H Rigneault, M Rosseneu, G Chimini.   

Abstract

The identification of defects in ABCA1 as the molecular basis of Tangier disease has highlighted its crucial role in the loading with phospholipids and cholesterol of nascent apolipoprotein particles. Indeed the expression of ABCA1 affects apolipoprotein A-I (apoA-I)-mediated removal of lipids from cell membranes, and the possible role of ABCA1 as an apoA-I surface receptor has been recently suggested. In the present study, we have investigated the role of the ABCA1 transporter as an apoA-I receptor with the analysis of a panel of transfectants expressing functional or mutant forms of ABCA1. We provide experimental evidence that the forced expression of a functional ABCA1 transporter confers surface competence for apoA-I binding. This, however, appears to be dependent on ABCA1 function. Structurally intact but ATPase-deficient forms of the transporter fail to elicit a specific cell association of the ligand. In addition the diffusion parameters of membrane-associated apoA-I indicate an interaction with membrane lipids rather than proteins. These results do not support a direct molecular interaction between ABCA1 and apoA-I, but rather suggest that the ABCA1-induced modification of the lipid distribution in the membrane, evidenced by the phosphatidylserine exofacial flopping, generates a biophysical microenvironment required for the docking of apoA-I at the cell surface.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11150301     DOI: 10.1074/jbc.M010265200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

Review 1.  Regulation and mechanisms of macrophage cholesterol efflux.

Authors:  Alan R Tall; Philippe Costet; Nan Wang
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

2.  Characterization of apoA-I-dependent lipid efflux from adipocytes and role of ABCA1.

Authors:  Alisha D Howard; Philip B Verghese; Estela L Arrese; Jose L Soulages
Journal:  Mol Cell Biochem       Date:  2010-06-10       Impact factor: 3.396

Review 3.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids.

Authors:  Guo-Jun Zhao; Kai Yin; Yu-Chang Fu; Chao-Ke Tang
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

Review 5.  Role of apolipoproteins in gammadelta and NKT cell-mediated innate immunity.

Authors:  Eric Champagne; Laurent O Martinez; Pierre Vantourout; Xavier Collet; Ronald Barbaras
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 6.  Is ABCA1 a lipid transfer protein?

Authors:  Michael C Phillips
Journal:  J Lipid Res       Date:  2018-01-05       Impact factor: 5.922

7.  Model system for the analysis of cell surface expression of human ABCA1.

Authors:  Ildikó Kasza; Zoltán Hegyi; Katalin Szabó; Hajnalka Andrikovics; Katalin Német; András Váradi; Balázs Sarkadi; László Homolya
Journal:  BMC Cell Biol       Date:  2009-12-21       Impact factor: 4.241

Review 8.  High density lipoprotein structure-function and role in reverse cholesterol transport.

Authors:  Sissel Lund-Katz; Michael C Phillips
Journal:  Subcell Biochem       Date:  2010

Review 9.  Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL.

Authors:  Vassilis I Zannis; Angeliki Chroni; Monty Krieger
Journal:  J Mol Med (Berl)       Date:  2006-02-25       Impact factor: 4.599

10.  Brefeldin A inhibits cholesterol efflux without affecting the rate of cellular uptake and re-secretion of apolipoprotein A-I in adipocytes.

Authors:  Philip B Verghese; Estela L Arrese; Alisha D Howard; Jose L Soulages
Journal:  Arch Biochem Biophys       Date:  2008-08-07       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.